Index

A
AAD. See Antiarrhythmic drugs (AAD)
AATAC. See Ablation versus amiodarone for treatment of afib in patients with CHF
Ablation catheter, 38
Ablation endpoints. See Catheter ablation, endpoints for
Ablation procedure anticoagulation during, 79–80, 79f
balloon-based, 42
in chronic AF, outcomes of, 45t
Ablation versus amiodarone for treatment of Afib in patients with CHF, 155
Ablation versus medical rate control for atrial fibrillation in patients with heart failure (ARC-HF), 156
Achilles heel, 42
Action potential duration (APD), 49
Activated clotting time (ACT), 93
Actuarial atrial arrhythmia, 121
Acute coronary artery injury, 101–102
Adenosine following pulmonary vein isolation to target dormant conduction elimination (ADVICE) study, 64
AF (atrial fibrillation) Nests. See Fibrillar myocardium
AFEQT scale, 144
Air emboli, 102
Air filters, 102
ALARA principle (as low as reasonably achievable), 176
Algorithms, 46
American Accreditation Council of Graduate Medical Education (ACGME), 180
AMICA. See Atrial fibrillation management in congestive heart failure with ablation (AMICA)
Amigo robotic arm, 55
Amiodarone, 130
Anatomy of structures. See under Atrial fibrillation (AF) ablation
Anesthesia, 71–72
Aneurysmal fossa, 6
Angioplasty, 95
Antiarrhythmic drugs (AAD), 70, 72, 74, 120, 121, 127, 128f, 129, 130, 133, 143
for sinus rhythm, 137–141, 138t, 139t–140t
treatment, 139t–140t
Antiarrhythmic therapy, 74
Anticoagulation, 70, 72, 166
periprocedural and long-term during ablation procedure, 79–80, 79f
outline of, 77–78
postablation, 81–82
preablation anticoagulation and TEE, 78–79
Antithrombotic drug therapy, 155
Antrum, 39
ARC-HF. See Ablation versus medical rate control for atrial fibrillation in patients with heart failure (ARC-HF)
Argon technology, 163
Arrhythmia, 7, 20
Aspirin, 72, 81
Atrial contractility, adverse impact on, 106–107
Atrial fibrillation (AF)
causes of, 22t
pathogenesis
diseases associated with, 20–21
electrophysiological mechanisms, 24–28, 25f
fibrosis, role of, 20–21
 genetic factors and ion channel
diseases, 21–23, 22f
 in postablation patients, asymptomatic, 73t
detection methods of, 73t
 sources of, 25t
Atrial fibrillation (AF) ablation. See also
 Catheter ablation; Clinical trials on
 atrial fibrillation
 anatomy of structures
 atrial septum/fossa ovalis, 5–6, 5f, 6t
esophagus, 15, 15f
ganglionic plexi, 11–14, 13f, 14f
left atrial appendage, 8–9, 9f
left atrial ridge and ligament of
marshall, 9–10
left atrium, 2–4, 2f, 3f
mitral isthmus, 10
phrenic nerves (PN), 14–15
pulmonary veins (PV), 4–5
superior vena cava, 7–8, 7f
 complications of, 87t–89t
and cost-effectiveness (See
Cost-effectiveness and AF ablation)
Atrial fibrillation (AF) catheter ablation
autonomic ganglionic plexi (GP)
ablation, 49
circumferential PV ablation, 38–39, 39f
electrogram-based ablation/CFAE
ablation, 44–46, 45f, 46f, 47f, 47t
future technologies, 55
left atrial ganglionic plexi (GP)
catheter ablation of, 50, 51
localization by endocardial
high-frequency stimulation (HFS), 49,
50, 51f, 52f
linear lesions, 46, 47–49, 47f
outline of, 35, 36f
pulmonary vein isolation (PVI), 36–38,
37f, 37t
circumferential/antral, 39–42, 41f
segmental/ostial, 38
tools for, 42–44
real-time spectral mapping in sinus
rhythm, 53
sequential ablation strategy, 53, 54f
Atrial fibrillation management in congestive
heart failure with ablation (AMICA),
155–156
Atrial macroreentrant tachycardia, 178
Atrial muscle, 3D anatomical structure of, 26
Atrial septum/fossa ovalis, 5–6, 5f, 6t
Atrial tachycardia, 38, 64
AtriCure, 164
Atrioesophageal fistulas, 42, 48, 99–101, 99f,
100f
Atriotomy, 167, 168f
Autonomic ganglionic plexi (GP)
ablation, 65–66
Autonomic tone, role of, 27
B
Bachmann’s bundle, 10
Balloon-based ablation technologies, 42
Basic electrophysiological studies, 178
and ablation procedure, 180–181
Bilateral thorascopic approach, 170
Biosense Webster, 55
Bipolar radiofrequency clamp devices, 165
Blanking period, 119
Brokeenbrough needles, 180
C
CABANA. See Catheter ABlation versus
ANTIarrhythmic drug therapy for
Atrial Fibrillation
Cadaver, 15f
Canadian Cardiovascular Society
Committee, 180
Canine model, 162
Cardiac tamponade, 85–91, 86f, 87t–89t
Cardiopulmonary exercise test, 156
Cardioversion
versus catheter ablation, 157
electrical, 72
Carina, 5
CARTO mapping, 44
CASTLE-AF, 154
Catheter ablation, 107
effectiveness of (See under Clinical trials
on atrial fibrillation)
efficacy of
acute efficacy, 119–120
failure mechanisms of, 122–123
mid- to long-term efficacy, 120–121, 120t
Index

Catheter ablation (Continued )
in nonparoxysmal AF, 122
success, definition of, 118–119
very long-term efficacy, 121–122
of ganglionated plexi (GP), 50, 51
Catheter ablation, endpoints for
autonomic GP ablation, 65–66
coronary sinus, 66
electrogram-based ablation/CFAEs
ablation, 64–65
linear lesions, 65
outline of, 61–62, 63t, 66t
PV isolation, 62, 63–64
thoracic veins ablation, 66
Catheter ablation for the cure of atrial
fibrillation (CACAF) multicenter, 120
Catheter ablation versus antiarrhythmic
drug therapy for atrial fibrillation
(CABANA), 121, 134
Catheter entrapment in MV/PV, 102–103
Catheterization, 5
laboratories, 176
Catheter Robotics, 55
Catheter tip contact force sensing, 91
CCS-SAF, 144
Char, 80
Chest tube, 171
Chest X-ray, 98f
Chronic atrial fibrillation, 157
Cineangiography, 107
Circuits, 103
Circular mapping catheter (CMC), 38, 40,
41f, 79f
Circumferential/antral PVI, 39–42, 41f
Circumferential PV ablation, 38–39, 39f
Cleveland Clinic group, 7
Clinical trials on atrial fibrillation
AAD for sinus rhythm, 137–141, 138t,
139t–140t
complications, 142–143
economic aspects, 143
effectiveness of catheter ablation
MANTRA-PAF, 155
RAAFT-2, 154–155
heart failure, patients with
AATAC, 155
AMICA, 155–156
ARC-HF, 156
list of trials, 144, 145t–132t
meta-analyses of randomized trials, 142
mortality, hospitalizations, and stroke,
trials on
CABANA, 144–153, 145t–152t
CASTLE-AF, 154
EAST, 153–154
persistent AF, in patients with
cardioversion versus catheter ablation,
157
radiofrequency catheter ablation, 157
SARA, 156–157
perspectives onto measuring QoL in AF
trials, 143–144
QoL, symptoms, and hospitalization,
141–142
survival and TEs, effect on, 142
Complex fractionated atrial electrogram
(CFAE)
ablation, 44–46, 45t, 46t, 47f, 47t, 50, 64–65
distributions, 46t, 47t
Complications, management of, 181
Complications, periprocedural and late
acute coronary artery injury, 101–102
air emboli, 102
atrial contractility, adverse impact on,
106–107
atrioesophageal fistulas, 99–101, 99f, 100f
cardiac tamponade, 85–91, 86t, 87t–89t
in catheter ablation studies, 86t
catheter entrapment in MV/PV, 102–103
left atrial tachyarrhythmias, organized,
103–106, 104t
periesophageal vagal injury, 101
phrenic nerve (PN) injury, 95–99, 96t, 97t
pulmonary veins (PV) stenosis, 94–95
radiation exposure during catheter
ablation of AF, 107
thromboembolic events
early postablation, 91–92
late postablation, 92
prevention of, 92–94
vascular complications, 101
Computed tomographic (CT) scan, 97f
spiral, 71
Conduction recovery, 47f
Congestive heart failure hypertension age
diabetes stroke (CHADS), 78, 93, 166,
177
Contact force sensing technology, 55

Catheter entrapment in MV/PV, 102–103
Catheter Robotics, 55
Catheter tip contact force sensing, 91
CCS-SAF, 144
Char, 80
Chest tube, 171
Chest X-ray, 98f
Chronic atrial fibrillation, 157
Cineangiography, 107
Circuits, 103
Circular mapping catheter (CMC), 38, 40,
41f, 79f
Circumferential/antral PVI, 39–42, 41f
Circumferential PV ablation, 38–39, 39f
Cleveland Clinic group, 7
Clinical trials on atrial fibrillation
AAD for sinus rhythm, 137–141, 138t,
139t–140t
complications, 142–143
economic aspects, 143
effectiveness of catheter ablation
MANTRA-PAF, 155
RAAFT-2, 154–155
heart failure, patients with
AATAC, 155
AMICA, 155–156
ARC-HF, 156
list of trials, 144, 145t–132t
meta-analyses of randomized trials, 142
mortality, hospitalizations, and stroke,
trials on
CABANA, 144–153, 145t–152t
CASTLE-AF, 154
EAST, 153–154
persistent AF, in patients with
cardioversion versus catheter ablation,
157
radiofrequency catheter ablation, 157
SARA, 156–157
perspectives onto measuring QoL in AF
trials, 143–144
QoL, symptoms, and hospitalization,
141–142
survival and TEs, effect on, 142
Complex fractionated atrial electrogram
(CFAE)
ablation, 44–46, 45t, 46t, 47f, 47t, 50, 64–65
distributions, 46t, 47t
Complications, management of, 181
Complications, periprocedural and late
acute coronary artery injury, 101–102
air emboli, 102
atrial contractility, adverse impact on,
106–107
atrioesophageal fistulas, 99–101, 99f, 100f
cardiac tamponade, 85–91, 86t, 87t–89t
in catheter ablation studies, 86t
catheter entrapment in MV/PV, 102–103
left atrial tachyarrhythmias, organized,
103–106, 104t
periesophageal vagal injury, 101
phrenic nerve (PN) injury, 95–99, 96t, 97t
pulmonary veins (PV) stenosis, 94–95
radiation exposure during catheter
ablation of AF, 107
thromboembolic events
early postablation, 91–92
late postablation, 92
prevention of, 92–94
vascular complications, 101
Computed tomographic (CT) scan, 97f
spiral, 71
Conduction recovery, 47f
Congestive heart failure hypertension age
diabetes stroke (CHADS), 78, 93, 166,
177
Contact force sensing technology, 55
Continuous fractionated atrial potentials, 51f
Conventional mapping catheter, 65
Coronary sinus (CS), 66
Cost-effectiveness and AF ablation
cost-effectiveness, 129–135, 131f, 132f
indications to catheter ablation, 127–129, 128f
Cox-maze procedure (CMP), 163f, 167, 167f,
168, 168f
development of, 162–164, 163f
C-reactive protein, 28
Crista terminalis, 26
Cryoablation, 42, 164
Cryoablation balloon technology, 121
Cryothermy, 42
D
Dabigatran, 78, 82, 94
Dallas Lesion Set, 170, 171
Dedifferentiation, 27
Defragmentation, 64, 65
3D mapping systems, 178–179
Dominant frequency (DF) gradient, 26
Doppler measurements, 95, 96f
Drug treatments, 70

E
Early treatment of atrial fibrillation for stroke prevention trial (EAST), 121
EAST. See Early treatment of atrial fibrillation for stroke prevention trial
Echocardiography, 4, 74
Efficacy of AF ablation. See under Catheter ablation
Elastic van Geison stain, 3f
Electrical cardioversion, 72
Electrical isolation of PV, 141
Electrical remodeling, 27, 170
Electroanatomic mapping (EAM), 107
3D, 38
Electrogram-based ablation, 54–65
and CFAE ablation, 44–46, 45f, 46f, 47f, 47t
Electrograms, 46, 51f
interpretation of, 178
Electrophysiological mechanisms
autonomic tone, role of, 27
inflammation, role of, 28
structural and electrical remodeling, 27

third dimension (anatomical structure),
26–27
trigger and AF sources, 24–26, 25f
Electrophysiologists, 99
Elucidation, 23
Endoscopy, 100
Endosense catheter, 55
Endpoints for catheter ablation for AF, 63t.
See also Catheter ablation, endpoints for
Ensite NavX electroanatomical mapping system, 55
Epicardial ganglion, 13
Epicardial neural plexus, human, 12
Esophagus, 15, 15f
European Heart Rhythm Association (EHRA), 180
Euroqol (EQ-5D), 143
Extracellular matrix (ECM), 28

F
Femoral hematomas, 79
Fentanyl, 71
Fibrillar myocardium, 53, 54f
Fibrosis, role of, 20–21
Fibrous pericardium, 14
Financial resources, 131f
Fistulas, atrioesophageal, 99–101, 99f, 100f
Floppy catheter, 43
Fluoroscopy, 5, 43, 97, 107, 178, 180
Flutter, 64, 103
Focal triggers, 36
Fossa ovalis, 5–6, 5f, 6t
Fractionated atrial potentials (FAP), 36, 51f,
52f

G
Ganglia, 12
Ganglionic plexi (GP), 11–14, 13f, 14f
ablation, autonomic, 49, 65–66. See also
Left atrial ganglionated plexi (GP)
Genetic linkage analyses, 21–23, 22f
Genome-wide association studies (GWAS), 23
Grass stimulator, 49

H
Health care system, UK, 132
Heart failure, patients with. See under
Clinical trials on atrial fibrillation
Index

Heart Rhythm Society Ad Hoc Committee on Catheter Ablation, 180
Heart Rhythm Society Consensus Statement, 118
Hematomas, 79
Hematoxylin–eosin stain, 13f
Heparin, 80, 93
High-frequency stimulation (HFS), endocardial, 49, 50, 51f, 52f
High-intensity frequency ultrasound (HiFU), 165–166
Holter monitors, 119
Hospital equipment/facilities/technological requirements, 176–177

I
Iatrogenic postatrial fibrillation ablation, 104t
Implantable cardioverter defibrillator/cardiac resynchronization therapy + defibrillator (ICD/CRTD), 155
Incremental cost-effectiveness ratio (ICER), 133
of ablation, 131
Inferior left atrial wall, 15
Inflammation, role of, 28
Intention to treat (ITT) analysis, 141
Intercostal space (ICS), 170
Intermediate fractionated atrial potentials, 51f
Interpulmonary isthmus, 5
Intracardiac echocardiography (ICE), 8, 40, 79, 79f, 91, 92, 96f, 100, 180
Intracellular calcium dysregulation, 28
Intrinsic cardiac autonomic nervous system, 49
Invasive electrophysiology procedures, 176
Ion channel diseases, 21–23, 22f
Ipsilateral PV, 5
Italian National Health Service (INHS), 133

K
Knowledge. See also Training and knowledge anatomical, 178
in basic electrophysiological studies, 178
of 3D mapping systems, 178–179
Lead shielding, 107
Left atrial appendage (LAA), 8–9, 9f, 49, 90
Left atrial ganglionated plexi. See under Atrial fibrillation catheter ablation
Left atrial ridge, 9–10
Left atrial size, 71
Left atrial tachyarrhythmias, organized, 103–106, 104t
Left atrial tachycardia/flutter (LAT/FL), 104t
Left atrium ejection fraction (LAEF), 106
Left atrium (LA), 2–4, 2f, 3f
Left atrium radiofrequency ablation (LARFA), 94
Left inferior pulmonary vein (LIPV), 36f, 96f, 97f
Left superior pulmonary vein (LSPV), 36f, 96f, 99f
Ligament of Marshall, 9–10, 171
Linear ablation strategies, 168
Linear lesions, 46, 47–49, 47f, 65
Lipomatous hypertrophy, 6
Lone AF, 20, 21
Low molecular weight heparin (LMWH), 81, 92, 94

M
Macroreentrant circuit, 103
Macroreentrant tachycardia, 65, 178
Magnetcосновы, 55
Magnetic field, 43
Magnetic shielding, 55
MANTRA-PAF, 147t. See also Radiofrequency ablation versus antiarrhythmic drug treatment in paroxysmal atrial fibrillation (MANTRA–PAF)
Mapping, computerized high-density, 4
Masson’s trichrome stain, 3f, 11f
Matrix metalloproteinases (MMP), 28
Maze procedure, 163f
Medtronic, 164
Microwave energy, epicardial, 168
Microwave radiometry, 55
Minithoracotomy, 167
Mitrall isthmus, 10, 11f
Mortality, hospitalizations, and stroke, trials on. See under Clinical trials on atrial fibrillation
Multicenter registry, 171
Multielectrode arrays, 38
Myocardial fibers, 3

N
Nerve fibers, 14f
Nitrous oxide, 164
Nonfluoroscopic intracardiac 3D orientation, 179
Nonpharmacologic therapy of AF, 128f
Normal sinus rhythm (NSR), 131, 133

O
Open-heart surgery, 86
Oral anticoagulation, 81
Oral warfarin anticoagulation, 72
Ostium, 94

P
Pacemaker therapy, 144
Pathogenesis. See under Atrial fibrillation (AF)
Patient management during ablation
antiarrhythmic drugs/electrical cardioversion, 72
anticoagulation, 72
sedation/anesthesia, 71–72
antiarrhythmic therapy, 74
late surveillance, 74–75
postprocedural management, 72
preablation fasting, 71
preablation management
anticoagulation therapy, 70
drug treatments, 70
imaging studies, 71
transesophageal echocardiogram (TEE), 70–71
rhythm outcome, 72–74, 73t
Pectinate muscles, 2
Pericardial effusion, 85
Pericardial tamponade, 72
Pericardiophrenic artery, 14
Pericarditic discomfort, 72
Periesophageal vagal injury, 101
Persistent atrial fibrillation. See under Clinical trials on atrial fibrillation patients with (See under Clinical trials on atrial fibrillation)
Phrenic nerve (PN), 14–15
injury, 95–99, 96t, 97t
Pitx2c, 23
Postablation anticoagulation, 81–82
Posterior left atrial wall, 15, 15f
Potassium current, 23
Preablation anticoagulation and TEE, 78–79
Preablation fasting, 71
Preablation patient management. See under patient management
Prospective, randomized, open-label, blinded outcome assessment (PROBE) trials, 154
Protamine infusion, 80
Pseudoaneurysm, treatment of, 101
Pulmonary vein isolation (PVI), 62, 63–64.
See also under Atrial fibrillation (AF) catheter ablation
expanded lesion sets, hybrid, 168–172
tools for, 42–44
Pulmonary vein (PV), 4–5
ablation, techniques of, 37t
stenosis, 94–95
Puncture, 5
Purkinje cells, 4

Q
QoL. See Quality of life
Quality-adjusted life year (QALY), 129, 131, 135
Quality of life (QoL), 130, 133, 135, 177
in AF trials, measuring, 143–144
symptoms, and hospitalization, 141–142

R
RAAFT. See Radiofrequency Ablation versus antiarrhythmic drugs for atrial fibrillation treatment
Radiation exposure, 107
during catheter ablation of AF, 107
Radiofrequency ablation versus antiarrhythmic drugs for atrial fibrillation treatment (RAAFT), 121, 154–155
Radiofrequency ablation versus antiarrhythmic drug treatment in paroxysmal atrial fibrillation (MANTRA-PAF), 155
Radiofrequency catheter ablation (RFCA), 40, 80, 91, 132t, 157
Radiofrequency clamp devices, 165
Radiofrequency energy, 139t–140t
Real-time spectral mapping in sinus rhythm, 53
Remodeling, 27, 170
Remote magnetic mapping, 55
Retraction sutures, 170
Rhythm-control therapy, 153, 154, 256
Rhythm outcome of patient management, 72–74, 73t
Right inferior pulmonary vein (RIPV), 36f
Right superior pulmonary vein (RSPV), 36f, 95, 97, 98f
Robotic technologies, 43

S
SARA. See Study of ablation versus antiarrhythmic drugs in persistent atrial fibrillation
Sedation/anesthesia, 71–72
Segmental/ostial PV isolation, 38
Sensitivity, 133
Septal aneurysm, 6
Septum, 64
Sequential ablation strategy, 53, 54f
Sequential radiofrequency applications, 63
Severity of AF scale, physician administered, 144
Sheaths, 93, 102, 180
Shox2, 23
Sinus rhythm, 53, 91
Skin radiation, 107
Sniff test, 97
Stand-alone atrial fibrillation, 166
Stenosis, PV, 94–95
Sternotomy, 167
Stroke, 77
periprocedural, 93
prophylaxis, 8
Structural heart disease (SHD), 20, 26, 128

Study of ablation versus antiarrhythmic drugs in persistent atrial fibrillation, 156–157
Subplexuses, 12
Superior vena cava (SVC), 3f, 7–8, 7f, 8
Surgical approach ablation technology
cryoablation, 164
high-intensity frequency ultrasound (HiFU), 165–166
unipolar RF energy, 164–165
CMP, development of, 162–164, 163f
historical aspects, 161–162
indications for, 166
PVI, expanded lesion sets, hybrid, 168–172
techniques and outcomes
Cox-maze procedure, 167, 167f, 168f
outcomes, 168
Surveillance, late, 74–75
Survival and thromboembolic events, 142
Symptomatic atrial fibrillation, 139t–140t
Systolic function, 71

T
Tachyarrhythmias, 64
left atrial, 103–106, 104t
Tachycardias, 48, 105, 178
Technical competence. See under Training and knowledge
Technical skills, basic, 179, 179t
Thermal ablation, 165
Thoracic veins ablation, 66
Thromboembolic events (TE). See under Complications, periprocedural and late
Thromboembolism, 78, 80, 81
Thrombus, 79
Trainees, 178, 179, 181
Training and knowledge. See also Knowledge anatomical knowledge, 178
electrograms, interpretation of, 178
follow-up, 181–182
indications and patient selection, 177
Index 191

technical competence
  basic electrophysiological studies and
  ablation procedure, 180–181
  basic technical skills, 179, 179t
  complications, management of, 181
  transeptal puncture, 179, 180
Transesophageal echocardiogram (TEE),
  70–71, 78–79, 180
Transgenic mouse, 23
Transillumination, 9f
Transitional cells, 4
Transseptal catheterization procedure, 6
Transseptal puncture, 179, 180
Transseptal puncture (TSP), 90, 91
Transthoracic echocardiogram, 71
Trichrome azan stain, 13f
Trigger and AF sources, 24–26, 25f

U
  Unipolar radiofrequency (RF) energy,
    164–165

V
  Vagal episodes, 72
  Vagal stimulation, 27
  Vascular complications, 101
  Vein of Marshall, 66
  Venice Chart Guidelines in 2007, 118
  Video-assisted bilateral PV antral isolation,
    168
  Vitamin K antagonist, 79

W
  Warfarin, 81, 93, 177